Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Unknown 2Completed 2

Sponsor Class

OTHER 4

Study Type

Observational 2Interventional 2

Sponsor

Cancer Type

Endocrine 4Thoracic 1Lymphoid 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neuroendocrine Tumors 378Pituitary Neoplasms 159Multiple Endocrine Neoplasia Type 1 150Thyroid Cancer, Papillary 122Pheochromocytoma 107Carcinoma, Neuroendocrine 93Thyroid Neoplasms 74Paraganglioma 68Carcinoid Tumor 66Neoplasms 54Thyroid Carcinoma, Anaplastic 50Adrenocortical Carcinoma 47Adrenal Gland Neoplasms 46Neoplasm Metastasis 40Insulinoma 39Pancreatic Neoplasms 36Gastro-enteropancreatic neuroendocrine tumor 36Adenoma, Islet Cell 36Carcinoma, Medullary 29Neuroblastoma 28Adenocarcinoma, Follicular 28Hyperaldosteronism 25Prostatic Neoplasms 24Lung Neoplasms 24Obesity 23Brain Neoplasms 22Pituitary Diseases 21Differentiated Thyroid Cancer 20Cushing Syndrome 20Sarcoma 19

Interventions

candesartan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Essential Hypertension × Endocrine × Clear all
NCT01022515 2026-02-06

PHEO

University Hospital, Rouen

Phase NA Completed
60 enrolled
CNSEndocrine

Essential Hypertension, Hypertension, Paraganglioma, Pheochromocytoma

NCT06500000 2024-07-15

The Plasma Metabolomics Profiling of Primary Aldosteronism

Third Military Medical University

Completed
95 enrolled
Endocrine

Essential Hypertension, Hyperaldosteronism, Adrenocortical Adenoma

NCT06090617 2024-03-19

WHYSKI

University Hospital Padova

Unknown
35 enrolled
Endocrine

Essential Hypertension, Hyperaldosteronism, Hypertension, Adrenocortical Adenoma

NCT01629225 2014-11-18

GRK4 Polymorphisms Blood Pressure Response to Candesartan

Third Military Medical University

Phase 4 Unknown
500 enrolled
Endocrine

Essential Hypertension, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡